ETV1(Ets variant 1) is a member of ETS transcription factor family, which has become the research focus in cancer and cardiac electrophysiology in recent years. TMPRSS2-ETV1 gene fusion exists in about 1-2% of prostate cancer, while ETV1 is highly expressed in 5-10% of advanced tumors. Different from sibling factor ERG, ETV1 not only enhances the signal of androgen receptor (AR), but also can autonomously activate testosterone synthesis and cholesterol/lipid metabolism reprogramming, cooperate with PTEN deficiency to promote the progress of local cancer to invasive adenocarcinoma, and predict higher Gleason score and poor prognosis, so it is regarded as an invasive subtype marker of "metabolism-transcription dual drive".